TGTX: Major Data Presentation for BRIUMVI® This Week!

Introduction

TG Therapeutics (NASDAQ: TGTX) is a commercial-stage biotech focused on B-cell mediated diseases, most notably multiple sclerosis (MS). Its flagship product BRIUMVI® (ublituximab-xiiy) is a monoclonal antibody targeting CD20 B-cells, approved for adults with relapsing forms of MS including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS (ir.tgtherapeutics.com). BRIUMVI launched in the U.S. in January 2023 following FDA approval (www.sec.gov), and in early 2024 it became available in Europe via partner Neuraxpharm (starting in Germany) (www.sec.gov). This week, a major data presentation at a medical conference is highlighting new BRIUMVI results. At the American Academy of Neurology (AAN) 2025 meeting, TGTX is showcasing five-year follow-up data from its Phase 3 ULTIMATE I & II trials, real-world infusion tolerability, an observational Phase 4 study, and other analyses of BRIUMVI in MS (www.stocktitan.net). The market has reacted positively to such updates – for instance, the stock jumped ~9% on the news of these upcoming presentations (www.stocktitan.net) – reflecting investor optimism that long-term data could bolster BRIUMVI’s competitive position.

Dividend Policy & Yield

TGTX does not pay a dividend. In fact, the company has never declared or paid cash dividends on its common stock (www.sec.gov). Management directs cash toward development and commercialization efforts rather than shareholder payouts – a typical stance for growth-focused biotechs. Moreover, the company’s new debt agreement prohibits cash dividends, a restriction expected to remain in effect going forward (www.sec.gov). With no dividend history or current yield to consider, investors in TGTX are relying entirely on stock price appreciation for returns.

Leverage and Debt Maturities

TGTX significantly increased its leverage in 2024 to support BRIUMVI’s launch and operations. On August 2, 2024, the company entered a $250 million term loan facility with Blue Owl Capital and repaid its prior loan with Hercules Capital (www.sec.gov). The new term loan matures in August 2029 and includes an option for an additional $100 million facility if needed (www.sec.gov). It carries a floating interest rate (SOFR or base rate + margin) with a stepped-down margin if BRIUMVI sales reach certain thresholds (www.sec.gov). The loan is secured by substantially all assets and requires quarterly principal amortization of $12.5 million beginning Q2 2028, with the bulk due at maturity (www.sec.gov). As of year-end 2024, total debt (loan payable) stood at about $244 million (www.sec.gov). Importantly, TGTX amassed a cash war chest of ~$311 million (cash + short-term investments) by Dec 31, 2024 (www.sec.gov), boosted by proceeds from the loan and a $140 million upfront payment from its EU partner. This leaves the company in a net cash position (cash exceeding debt by roughly $67 million), providing a cushion despite the sizeable debt. Overall leverage appears moderate relative to the rapidly growing revenue base, but the debt is substantial for a single-product biotech and adds fixed obligations.

Liquidity and Coverage

TGTX’s liquidity profile is healthy in the near term. Management stated that its cash on hand plus projected BRIUMVI revenues will provide “sufficient liquidity for more than a twelve-month period” from the 2025 filing of the 10-K (www.sec.gov). In other words, the company does not anticipate needing to raise additional capital in the immediate future. This confidence stems from BRIUMVI’s commercial ramp and the $152.5 million in milestone payments received from ex-U.S. partners during 2023–2024 (www.sec.gov) (www.sec.gov). Notably, TGTX has even initiated shareholder returns via buybacks – in August 2024 the board approved a $100 million share repurchase program, with about $91 million remaining authorized at year-end (www.sec.gov).

Interest coverage appears manageable but bears watching. In 2024, TGTX incurred $24.0 million in interest expense, roughly doubling from $12.6 million in 2023 after taking on the new debt (www.sec.gov). That interest was largely covered by operating profits, as the company reported net income of $23.4 million in 2024 (www.sec.gov). By one measure, EBIT covered annual interest about 3× in 2024 – a reasonable, though not ample, cushion. With BRIUMVI sales climbing, interest expense should become a smaller proportion of earnings going forward. Additionally, loan covenants require TGTX to maintain certain cash balances and market cap levels (www.sec.gov), effectively forcing prudent liquidity management. So far, the company remains in compliance with all debt covenants (www.sec.gov). Overall, coverage of fixed charges is adequate given the strong revenue growth, but sustained execution is needed to comfortably service debt as the company scales.

Valuation and Growth Outlook

BRIUMVI’s commercial traction has been robust, underpinning a rapidly improving financial outlook for TGTX. Net product revenue jumped from only $2.6 million in 2022 (when BRIUMVI was pre-launch) to $92.0 million in 2023, and then surged to $313.7 million in 2024 (www.sec.gov). This tripling of sales in 2024 reflects accelerating U.S. uptake as more MS patients initiate therapy and prescribers grow familiar with BRIUMVI’s profile. Even with this growth, BRIUMVI still holds a small share of the MS therapy market, indicating significant headroom. For perspective, Roche’s Ocrevus (the entrenched IV anti-CD20 therapy) generated $5.7 billion in the first nine months of 2024 (www.biocentury.com), and Novartis’s Kesimpta (a self-injectable anti-CD20) reached $2.3 billion in sales in the same 9-month period (www.biocentury.com). BRIUMVI’s ~$314 million full-year 2024 sales are a fraction of these figures, suggesting that capturing even single-digit percentage share of the market could translate into $1 billion+ annual revenues. TGTX’s management indeed believes BRIUMVI is a “multi-billion dollar” opportunity with room for substantial market share gains (www.globenewswire.com).

Financial guidance supports this bullish outlook. The company’s preliminary results for 2025 indicate ~$594 million in U.S. BRIUMVI revenue ($616 million globally) for the full year (www.globenewswire.com). Furthermore, TGTX is targeting $875–$900 million in global revenue in 2026, with $825–$850 million of that from U.S. BRIUMVI sales (www.globenewswire.com). Hitting these targets would imply ~45% top-line growth in 2026 and move BRIUMVI well into blockbuster territory. Profitability is expected to scale up as well – the company forecasts a 2026 operating expense budget of ~$350 million (excluding non-cash comp), which should allow a healthy operating margin if revenue approaches $900 million (www.globenewswire.com). Wall Street analysts have taken note of TGTX’s growth trajectory. The consensus price target has been nudged upward to roughly $45 per share, with major banks like JPMorgan recently lifting their targets to the high-$40s (simplywall.st) (simplywall.st). At a current share price around $30, TGTX trades at about 7.5× 2025E sales and ~5× 2026E sales, which many analysts view as reasonable or even undervalued for a high-growth biotech. By comparison, the stock’s P/E is not meaningful on trailing earnings (2024 EPS was only $0.15 (www.sec.gov)), but based on 2026 profit estimates the forward P/E would drop to the mid-teens – a relatively low multiple given the growth rate. Overall, the market appears to be pricing in some execution risk, but successful delivery on guidance could drive a re-rating closer to peer biotech valuations.

Risks and Red Flags

Despite the promising outlook, TGTX carries significant risks typical of a one-product biotech. BRIUMVI is essentially the company’s sole revenue source – an overdependence on a single drug that exposes investors to concentrated risk (simplywall.st). Any setback with BRIUMVI, whether commercial, clinical, or regulatory, could severely impact TGTX’s fortunes. For example, unexpected safety issues or subpar long-term efficacy could diminish physician confidence. (Notably, all anti-CD20 therapies carry risks like infusion reactions, infections, and immunoglobulin reductions; so far BRIUMVI’s profile has been in line with class expectations, and new 5-year data being presented are intended to reinforce its safety/efficacy consistency.) Competition is a major factor: TGTX is going up against pharma giants in the MS space. Roche’s Ocrevus and Novartis’s Kesimpta have deep market penetration and formidable resources behind them. Both incumbents continue to grow – Ocrevus hit $2 billion in sales in 3Q 2024 alone (www.biocentury.com) – meaning BRIUMVI must differentiate on factors like infusion convenience (a 1-hour infusion vs. Ocrevus’s longer infusion) or pricing. There is also competitive pressure from other drug classes; for instance, several oral BTK inhibitor pills are in late-stage development for MS. While the fate of these BTK inhibitors remains uncertain (www.biocentury.com), any breakthrough oral therapy could cut into the patient pool for infusion drugs. Over time, biosimilar competition may emerge as well – Ocrevus will face biosimilars later this decade, which could push payers to favor cheaper alternatives and put pricing pressure on BRIUMVI.

TGTX’s financial and strategic position introduces additional risks. The company has a leveraged balance sheet, and management itself warns that the level of debt and interest obligations could constrain operations or make funding needs harder to meet (www.sec.gov). If BRIUMVI sales disappoint, TGTX might struggle with its debt covenants or need to raise dilutive equity capital. Thus far the company has been prudent, but investors should monitor its cash burn relative to sales growth. Another flag is TGTX’s limited pipeline beyond BRIUMVI. The company does have an early-stage program (e.g. azer-cel, an allogeneic CAR-T therapy for autoimmune diseases), but it is years from commercialization and carries high development risk. In effect, TGTX is a “pipeline-in-a-product” story – great if BRIUMVI thrives, but with little backup if it falters. The company’s track record highlights this risk: TGTX’s prior drug UKONIQ (umbralisib) for cancer had to be withdrawn from the market in 2022 due to safety concerns (www.sec.gov), a setback that erased an entire franchise and left BRIUMVI as the sole focus. While MS is a very different indication, that episode underscores the volatility inherent in drug development and the importance of diligent pharmacovigilance. Lastly, regulatory and reimbursement risks persist. Gaining and maintaining favorable insurance coverage for BRIUMVI is critical – if payers impose onerous prior authorizations or higher patient cost-sharing, adoption could slow. The company must also navigate evolving health policy (e.g. drug pricing reforms) that could impact margins. In sum, investors face a range of risks: fierce competition, one-product concentration, debt leverage, and typical biotech uncertainties. These factors could lead to volatile performance and warrant careful due diligence.

Catalysts and Open Questions

Moving forward, several key catalysts and questions will shape TGTX’s story. In the immediate term, the new BRIUMVI data presentation is a catalyst – positive findings from the 5-year extension studies and real-world usage could help convince more neurologists and patients to choose BRIUMVI. Investors will be watching whether the data confirm durable efficacy (e.g. low relapse rates and MRI lesion control sustained over 5 years) and an acceptable long-term safety profile. Any surprises (good or bad) in this data dump could influence sales trends in upcoming quarters. Another major catalyst is the planned launch of a subcutaneous (self-administered) formulation of BRIUMVI. TGTX is developing a subcutaneous version to allow patients to self-inject, similar to Kesimpta. This could be transformative – roughly 35–40% of the anti-CD20 MS market is currently served by self-injectables (simplywall.st), a segment BRIUMVI doesn’t fully access with its IV-only format. A convenient subcutaneous BRIUMVI, if approved, would let TGTX compete directly for those patients and potentially expand BRIUMVI’s addressable market by a third or more】 (simplywall.st). The company has indicated that its Phase 3 trial for a modified dosing regimen (the ENHANCE study) has completed enrollment (simplywall.st), and it is also working on the formulation for self-injection. Progress on these fronts – data readouts or regulatory filings for the subcutaneous route – will be closely watched in 2025–2026.

Beyond MS, TGTX is exploring new indications and technologies. Management has hinted at pursuing additional autoimmune diseases for BRIUMVI (leveraging the B-cell depletion mechanism) and is undertaking exploratory studies to expand BRIUMVI “beyond MS” (www.globenewswire.com). Any concrete moves here (for example, trials in neuromyelitis optica or other B-cell driven conditions) could unlock new markets. Similarly, the allogeneic CAR-T program (azer-cel) targeting progressive MS is an intriguing long-term project – if successful, it could address progressive forms of MS that anti-CD20 antibodies don’t fully solve (www.globenewswire.com). However, that program is in early stages, so it remains more of a future optionality than an investable catalyst today.

Finally, an open question is strategic direction: will TGTX continue as an independent company or become a takeout candidate? The rapid revenue growth and de-risked U.S./EU approvals make TGTX a potential M&A target in the eyes of some analysts (simplywall.st). The company has even structured its Neuraxpharm deal with an option to buy back ex-U.S. rights in the event of a change of control (www.sec.gov), a provision likely meant to facilitate an easier acquisition. While there are no public indications of active buyout talks, the broader biotech environment has seen renewed dealmaking interest, and bullish observers consider TGTX’s profile attractive to larger neuro-focused companies (simplywall.st). In the meantime, TGTX must prove it can execute as a standalone – scaling up sales, further penetrating the MS market, and managing expenses to drive sustainable profits.

In conclusion, TG Therapeutics is at an inflection point. The upcoming BRIUMVI data presentation aims to solidify the drug’s credibility at a time when sales are climbing rapidly. The company’s fundamentals have improved markedly (rising revenues, two consecutive profitable years, ample cash), yet significant challenges and questions remain around competition, sustainability of growth, and strategic outcomes. How well TGTX navigates these next steps – including delivering on clinical data, expanding BRIUMVI’s reach (e.g. via a subcutaneous version), and prudently managing its finances – will determine if the recent momentum can be maintained. Investors should keep a close eye on this week’s BRIUMVI data updates**, as they could not only influence near-term stock sentiment but also answer vital questions about the drug’s long-term potential in the multi-billion-dollar MS market (www.globenewswire.com). The stakes are high for TGTX, but so is the opportunity if BRIUMVI continues on its upward trajectory.

For informational purposes only; not investment advice.